Cas:562836-64-0 4-(Methylsulfanyl)benzoic acid manufacturer & supplier

We serve Chemical Name:4-(Methylsulfanyl)benzoic acid CAS:562836-64-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-(Methylsulfanyl)benzoic acid

Chemical Name:4-(Methylsulfanyl)benzoic acid
CAS.NO:562836-64-0
Synonyms:4-(Methylsulfanyl)benzoic acid
Molecular Formula:C8H8O2S
Molecular Weight:168.21300
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:62.60000
Exact Mass:168.02500
LogP:2.10670

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-(Methylsulfanyl)benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(Methylsulfanyl)benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(Methylsulfanyl)benzoic acid Use and application,4-(Methylsulfanyl)benzoic acid technical grade,usp/ep/jp grade.


Related News: ��Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.�� 4-(Methylsulfanyl)benzoic acid manufacturer Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 4-(Methylsulfanyl)benzoic acid supplier Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 4-(Methylsulfanyl)benzoic acid vendor Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant. 4-(Methylsulfanyl)benzoic acid factory ��Once these risks have been identified then a project team can be put together combining the necessary expertise to provide the integrated services and tailored support to ensure continuity of supply from beginning to end.��